BIOTEST AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.7 EUR | 0.00% |
|
+0.35% | -7.42% |
| Apr. 19 | Biotest Launches New Plasma Collection Center in Germany | MT |
| Mar. 28 | Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- One of the major weak points of the company is its financial situation.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.42% | 1.49B | B- | ||
| -4.66% | 87.53B | A- | ||
| +1.32% | 40.42B | A- | ||
| -19.27% | 29.48B | B- | ||
| +57.86% | 25.43B | A | ||
| -17.69% | 11.49B | B- | ||
| -43.00% | 11.3B | B | ||
| -9.14% | 11.1B | D+ | ||
| +5.24% | 8.75B | B+ | ||
| -8.42% | 7.99B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
- Stock Market
- Equities
- BIO3 Stock
- Ratings Biotest AG
